Last update 19 Sep 2024

ALK x FAK1 x PYK2 x IGF-1R

Basic Info

Related Targets
ALKFAK1PYK2[+1]

Related

1
Drugs associated with ALK x FAK1 x PYK2 x IGF-1R
Conteltinib
Target
ALK x FAK1 x IGF-1R x PYK2
Mechanism
ALK inhibitors [+3]
Active Org.-
Originator Org.
Centaurus Biopharma Co., Ltd.
Active Indication
ALK positive Non-Small Cell Lung Cancer [+1]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
11
Clinical Trials associated with ALK x FAK1 x PYK2 x IGF-1R
CTR20222060 / RecruitingPhase 2
评价CT-707联合特瑞普利单抗注射液和吉西他滨在晚期胰腺癌患者中的安全性、耐受性、药代动力学和有效性的Ib/II 期研究
[Translation] Phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of CT-707 in combination with toripalimab injection and gemcitabine in patients with advanced pancreatic cancer
100 Clinical Results associated with ALK x FAK1 x PYK2 x IGF-1R
Login to view more data
100 Translational Medicine associated with ALK x FAK1 x PYK2 x IGF-1R
Login to view more data
0 Patents (Medical) associated with ALK x FAK1 x PYK2 x IGF-1R
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free